Radial Extracorporeal Shockwave Therapy (rESWT) is not superior to "minimal-dose" rESWT for patients with chronic plantar fasciopathy; a double-blinded randomised controlled trial
Wheeler, Patrick Dudson, Chloe Calver, Rachel
Wheeler, Patrick
Dudson, Chloe
Calver, Rachel
Abstract
Background: Investigating outcomes following radial-extra-corporeal-shockwave-therapy (rESWT) in patients with chronic plantar fasciopathy METHODS: This double-blinded RCT in a single NHS Sports medicine clinic recruited 117 patients with chronic plantar fasciopathy randomised equally to either 3 sessions of rESWT or "minimal-dose" respectively. Mean age 51.7 ± 9.6 years, 66 % female, symptom duration: 32.6 ± 30.8 months.
Results: "Average pain" improved by 50 % at 6-months, (>1/3 at interim time-points). Statistically significant within-group improvements were identified in pain, local function, and "ability" PROMs in both groups. Fewer benefits in activity levels or mood. No between-group differences were seen at the interim or final time-points.
Conclusion: 3 sessions of "recommended-dose" rESWT is non-superior to "minimal-dose" rESWT in patients with chronic plantar fasciopathy. rESWT may be ineffective in the treatment of patients with chronic plantar fasciopathy, "minimal-dose" rESWT may be sufficient for a therapeutic effect, or a greater number of treatment sessions may be required for benefit.
Level of evidence: Level I - Randomised controlled trial.
MIDER Authors
Citations
Altmetric:
Date
2022-07-01
Type
Article
Subject
Extracorporeal Shockwave Therapy, Outcome study, Pain, Plantar fasciopathy
Collections
Citation
Wheeler, P. C., Dudson, C., & Calver, R. (2022). Radial Extracorporeal Shockwave Therapy (rESWT) is not superior to "minimal-dose" rESWT for patients with chronic plantar fasciopathy; a double-blinded randomised controlled trial. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons, 28(8), 1356–1365. https://doi.org/10.1016/j.fas.2022.06.016